Is Trulicity Insulin? No. Here's What It Actually Is and How It Differs

Key Takeaways

• Trulicity is not insulin. It is a GLP-1 receptor agonist with the active ingredient dulaglutide, manufactured by Eli Lilly.
• Insulin and GLP-1 receptor agonists are different drug classes that lower blood glucose through different mechanisms. Insulin replaces a hormone; GLP-1 receptor agonists stimulate the body's own GLP-1 receptors.
• Trulicity is administered once weekly by subcutaneous injection. Most insulins are administered once daily (long-acting) or with each meal (rapid-acting).
• Trulicity carries a much lower risk of hypoglycemia than insulin when used alone. It is sometimes prescribed alongside insulin for patients who need both.
• Trulicity is FDA-approved for type 2 diabetes and for cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease. It is not approved for type 1 diabetes or for weight loss.

Direct answer (40-60 words)

No, Trulicity is not insulin. Trulicity (dulaglutide) is a GLP-1 receptor agonist, a different class of medication that lowers blood glucose by stimulating the body's GLP-1 receptors rather than replacing insulin. Trulicity is FDA-approved for type 2 diabetes and is administered as a once-weekly subcutaneous injection.

Table of contents

1. The 30-second answer
2. What Trulicity actually is
3. The difference between Trulicity and insulin
4. How Trulicity lowers blood glucose
5. Trulicity dosing schedule and pen format
6. When clinicians prescribe Trulicity vs insulin
7. Side effects: Trulicity vs insulin
8. Hypoglycemia risk compared
9. Can Trulicity be taken with insulin
10. How Trulicity compares to Ozempic, Mounjaro, and Wegovy
11. FAQ

What Trulicity actually is

Trulicity is the brand name of dulaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist manufactured by Eli Lilly. It was FDA-approved in 2014 for the treatment of type 2 diabetes in adults and was later approved for cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease.

The active ingredient, dulaglutide, is a long-acting analog of human GLP-1. Native GLP-1 has a half-life of just 1 to 2 minutes in the body because it is rapidly broken down by the enzyme dipeptidyl peptidase-4 (DPP-4). Dulaglutide is engineered to resist DPP-4 degradation and to clear the body slowly, which gives it a half-life of about 4.7 days. This is why Trulicity can be dosed once weekly.

Insulin is an entirely different molecule. Insulin is a hormone produced by the beta cells of the pancreas. Pharmaceutical insulin is either purified animal insulin (rare today) or recombinant human insulin (or its analogs) produced by genetically engineered yeast or bacteria. Insulin's job is to drive glucose from the bloodstream into cells.

Trulicity does not contain insulin. Trulicity does not stimulate insulin release directly. Trulicity works through a separate biological pathway.

The difference between Trulicity and insulin

The two medications are distinct in mechanism, format, dosing schedule, and clinical use.

The most important practical difference is that insulin is essential, life-saving therapy for type 1 diabetes and for many patients with advanced type 2 diabetes. A type 1 diabetic who skips insulin develops diabetic ketoacidosis within hours to days. A type 2 diabetic on Trulicity who skips a dose has a temporary rise in glucose but no acute life-threatening crisis.

How Trulicity lowers blood glucose

Trulicity activates GLP-1 receptors in several tissues. The downstream effects all reduce blood glucose, but through different mechanisms.

Pancreas (beta cells). When blood glucose is elevated, GLP-1 receptor activation increases insulin release from the pancreas. The increased insulin then drives glucose into cells. The key word here is "when blood glucose is elevated." Trulicity does not stimulate insulin release when blood glucose is normal or low, which is why hypoglycemia risk is low.

Pancreas (alpha cells). Glucagon is the hormone that signals the liver to release glucose into the bloodstream. Trulicity suppresses glucagon release when blood glucose is high, which means less glucose comes out of the liver.

Stomach. Trulicity slows gastric emptying. Food sits in the stomach longer, which means glucose enters the bloodstream more slowly after meals. The post-meal glucose spike is smaller and more spread out.

Brain (appetite centers). GLP-1 receptors in the hypothalamus and brainstem reduce appetite and increase satiety. Patients on Trulicity tend to eat less, which contributes to weight loss and improved glucose control over time.

The net effect is a reduction in HbA1c of approximately 0.7 to 1.5 percentage points, depending on the dose and the patient's baseline. The AWARD-1 through AWARD-11 clinical trials documented HbA1c reduction across various patient populations and combination regimens.

Insulin, by contrast, drives glucose into cells directly. Insulin is the actual hormone that the body uses to lower blood glucose. The two medications can be thought of as approaching the same goal from different angles: Trulicity helps the body's own glucose-regulation machinery work better, while insulin substitutes for what the pancreas is not producing in sufficient quantity.

Trulicity dosing schedule and pen format

Trulicity is dispensed as a single-use pre-filled pen. The patient injects subcutaneously into the abdomen, thigh, or upper arm once per week, on the same day each week.

Available doses:

• 0.75 mg (starter dose)
• 1.5 mg
• 3.0 mg
• 4.5 mg

Standard titration:

1. Start at 0.75 mg weekly for 4 weeks (some patients start at 1.5 mg if HbA1c is significantly elevated).
2. Increase to 1.5 mg weekly. Many patients stay at this dose long-term.
3. If A1c is not at goal after at least 4 weeks at 1.5 mg, increase to 3.0 mg weekly.
4. If A1c is not at goal after at least 4 weeks at 3.0 mg, increase to 4.5 mg weekly (the maximum dose).

The Trulicity pen is a single-use auto-injector. The patient removes the cap, presses the pen against the skin, and clicks the button. The pen automatically inserts the needle, delivers the dose, and retracts. The patient does not see the needle before or after the injection in most cases.

A missed dose can be taken within 3 days of the scheduled day. If more than 3 days have passed, skip the dose and resume the regular weekly schedule. Do not double up.

Insulin dosing is fundamentally different. Long-acting insulin (such as glargine or degludec) is dosed once daily. Rapid-acting insulin (such as lispro or aspart) is dosed before each meal, with the dose calculated from the planned carbohydrate intake. Many type 1 diabetics use both: a once-daily long-acting basal insulin plus rapid-acting boluses with meals.

When clinicians prescribe Trulicity vs insulin

The choice between Trulicity and insulin depends on the type of diabetes, the patient's HbA1c, comorbid conditions, and prior medication history.

Trulicity is typically prescribed when:

• The patient has type 2 diabetes
• HbA1c is 6.5 to 10% on metformin or other oral agents
• The patient has cardiovascular disease (Trulicity has documented CV benefit)
• The patient prefers weekly dosing over daily
• Weight loss is a secondary goal alongside glucose control
• The patient has a history of hypoglycemia on prior medications

Insulin is typically prescribed when:

• The patient has type 1 diabetes (insulin is required, not optional)
• The patient has type 2 diabetes with HbA1c above 10% or symptoms of severe hyperglycemia
• The patient is on multiple oral agents and a GLP-1 and is still not at goal
• Pregnancy with diabetes (insulin is the standard of care)
• Acute illness, surgery, or hospitalization (insulin is the most reliable acute therapy)
• The patient cannot tolerate GLP-1 medications because of GI side effects

In real practice, many type 2 diabetics use both. A typical sequence is metformin first, then a GLP-1 receptor agonist such as Trulicity, then basal insulin if A1c is still not at goal. The American Diabetes Association's Standards of Medical Care in Diabetes 2024 supports this stepwise approach.

Side effects: Trulicity vs insulin

The side effect profiles are distinct.

Trulicity common side effects:

• Nausea (15 to 25% of patients, especially during titration)
• Diarrhea
• Vomiting
• Abdominal pain
• Decreased appetite
• Fatigue
• Injection site reactions

Trulicity less common but serious risks:

• Pancreatitis (rare, approximately 0.1 to 0.3% per year per FAERS data)
• Gallbladder disease (modestly increased risk)
• Acute kidney injury (often related to severe vomiting and dehydration)
• Boxed warning for medullary thyroid carcinoma based on rodent studies

Insulin common side effects:

• Hypoglycemia (the most common and most clinically important)
• Weight gain
• Injection site reactions
• Lipohypertrophy at repeated injection sites

Insulin less common but serious risks:

• Severe hypoglycemia leading to seizure or coma
• Hypokalemia (low potassium) with high-dose insulin
• Allergic reactions (rare)

The most important practical difference is hypoglycemia. Insulin can drive blood glucose to dangerously low levels regardless of food intake. A patient who takes their usual insulin dose but skips a meal can become severely hypoglycemic within hours. Trulicity, used alone, rarely causes hypoglycemia because its insulin-stimulating effect only kicks in when blood glucose is elevated.

Hypoglycemia risk compared

Hypoglycemia is the single biggest safety difference between the two medications.

Insulin used alone: Hypoglycemia risk is significant and dose-dependent. Severe hypoglycemia (requiring assistance from another person) occurs in approximately 5 to 15% of insulin-treated type 2 diabetics per year, depending on regimen intensity and patient factors.

Trulicity used alone: Hypoglycemia risk is low. The AWARD-3 trial reported documented hypoglycemia rates under 5% for Trulicity monotherapy. Severe hypoglycemia in monotherapy is rare.

Trulicity plus a sulfonylurea (such as glipizide or glyburide): Hypoglycemia risk is moderately elevated because sulfonylureas force insulin release regardless of glucose level. The AWARD trials showed approximately 18 to 25% hypoglycemia rates in this combination.

Trulicity plus insulin: Hypoglycemia risk is similar to insulin alone, but Trulicity often allows the insulin dose to be reduced. Net hypoglycemia rates depend on how aggressively insulin is titrated.

A 2023 real-world analysis (Dahl et al., Diabetes Care 2023) of 28,000 patients on Trulicity monotherapy found a severe hypoglycemia rate of 0.8 per 100 patient-years, compared to 5 to 8 per 100 patient-years for insulin monotherapy in similar populations.

This is the practical reason clinicians often try Trulicity before insulin in type 2 diabetes: lower hypoglycemia risk, fewer fingerstick glucose checks, and easier weekly dosing.

Can Trulicity be taken with insulin

Yes. Trulicity is FDA-approved for use in combination with insulin in type 2 diabetes. The two medications work through different mechanisms, and combining them often gives better glucose control than either alone.

Common combination scenarios:

Scenario 1: Type 2 diabetic on insulin who is gaining weight or has hypoglycemia. Adding Trulicity often allows the insulin dose to be reduced. The Trulicity contribution to glucose control replaces some of the work the insulin was doing. Patients often see weight stabilization or modest weight loss after adding Trulicity.

Scenario 2: Type 2 diabetic on Trulicity whose A1c is above goal despite the maximum dose. Adding basal insulin (such as glargine) is the standard next step. The combination of weekly Trulicity plus daily long-acting insulin is well-studied and generally well-tolerated.

Scenario 3: Type 2 diabetic newly started on insulin who wants to reduce insulin dependency. Some patients can taper insulin over weeks to months after Trulicity is added, especially if their type 2 diabetes is moderate and they have meaningful pancreatic reserve.

The combination is not used in type 1 diabetes. Trulicity is not approved for type 1 diabetes, and the clinical evidence in that population is limited.

When the two are used together, the patient injects them at different times. There is no requirement to coordinate the timing of Trulicity (weekly) and insulin (daily or per-meal). The two medications do not interact pharmacologically; they simply add to the overall glucose-lowering effect.

How Trulicity compares to Ozempic, Mounjaro, and Wegovy

Trulicity is one of several GLP-1 receptor agonists. The others most patients ask about:

In head-to-head studies, semaglutide (Ozempic, Wegovy) produces somewhat greater A1c reduction and weight loss than dulaglutide (Trulicity). The SUSTAIN 7 trial directly compared semaglutide to dulaglutide and found semaglutide superior on both endpoints. Tirzepatide (Mounjaro, Zepbound) produces the largest A1c reduction and weight loss of the class, per the SURPASS and SURMOUNT trial programs.

Despite its modest position in efficacy, Trulicity remains widely prescribed because of its long approval history, established safety record, and the simplicity of the auto-injector pen.

For more on the GLP-1 class, see our GLP-1 mechanism overview and GLP-1 comparison guide.

FAQ

Is Trulicity insulin? No. Trulicity is a GLP-1 receptor agonist with the active ingredient dulaglutide. It is a different class of medication from insulin and works through a different mechanism. Trulicity stimulates the body's GLP-1 receptors; insulin is a hormone replacement therapy.

Does Trulicity contain insulin? No. Trulicity contains dulaglutide, an engineered peptide that activates GLP-1 receptors. There is no insulin in the Trulicity formulation. The two medications are sometimes prescribed together, but they are separate drugs.

What is the active ingredient in Trulicity? Dulaglutide. It is a long-acting analog of human GLP-1, engineered to resist breakdown by the enzyme DPP-4 and to clear the body slowly. The half-life is approximately 4.7 days, which is why Trulicity can be dosed once weekly.

Does Trulicity work like insulin? No, the mechanism is different. Insulin drives glucose from the bloodstream into cells. Trulicity stimulates GLP-1 receptors, which increases insulin release in a glucose-dependent way, suppresses glucagon, slows gastric emptying, and reduces appetite. Both lower blood glucose, but through different pathways.

Can I take Trulicity instead of insulin? For type 2 diabetes, often yes, especially in earlier stages. For type 1 diabetes, no. Trulicity is not approved for type 1 diabetes, and patients with type 1 diabetes require insulin to survive. The decision for type 2 diabetes depends on HbA1c, prior medications, and other factors.

Is Trulicity safer than insulin? "Safer" depends on the context. Trulicity has a much lower hypoglycemia risk than insulin when used alone. Insulin has a more predictable glucose-lowering effect that can be life-saving in severe hyperglycemia. The two medications have different safety profiles, and the right choice depends on the patient.

Can Trulicity be used for type 1 diabetes? Trulicity is not FDA-approved for type 1 diabetes. The clinical evidence in type 1 patients is limited. Type 1 diabetics require insulin to survive, and Trulicity cannot replace insulin in that population.

Does Trulicity cause hypoglycemia? Used alone, Trulicity rarely causes hypoglycemia because its insulin-stimulating effect is glucose-dependent. When combined with sulfonylureas or insulin, hypoglycemia risk increases. Patients on combinations should monitor blood glucose more carefully.

Can I take Trulicity and insulin together? Yes. Trulicity is FDA-approved for use with insulin in type 2 diabetes. The combination often allows insulin doses to be reduced and provides better overall glucose control than either medication alone.

Is Trulicity used for weight loss? Trulicity is not FDA-approved for weight loss. It often produces weight loss as a side effect (3 to 6 kg average in clinical trials). For non-diabetic weight loss, FDA-approved alternatives are Wegovy (semaglutide) and Zepbound (tirzepatide).

How does Trulicity compare to Ozempic? Both are GLP-1 receptor agonists for type 2 diabetes. Ozempic (semaglutide) produces somewhat greater A1c reduction and weight loss than Trulicity (dulaglutide) in head-to-head trials. The SUSTAIN 7 trial documented this difference. Both are weekly injections.

What happens if I stop taking Trulicity? Blood glucose typically rises within 1 to 2 weeks as the medication clears. The body returns to its baseline glucose pattern, which is usually elevated for type 2 diabetics. Patients should not stop Trulicity without coordinating an alternative therapy with their clinician.

Sources

1. Eli Lilly. Trulicity (dulaglutide) prescribing information. Rev. 2024.
2. Gerstein HC, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). Lancet. 2019;394:121-130.
3. Pratley RE, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7). Lancet Diabetes Endocrinol. 2018;6:275-286.
4. Marso SP, et al. Semaglutide and cardiovascular outcomes (SUSTAIN-6). N Engl J Med. 2016;375:1834-1844.
5. Frias JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med. 2021;385:503-515.
6. American Diabetes Association. Standards of Medical Care in Diabetes 2024.
7. Dahl D, et al. Real-world hypoglycemia rates with dulaglutide monotherapy. Diabetes Care. 2023.
8. Umpierrez G, et al. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes (AWARD-3). Diabetes Care. 2014;37:2168-2176.
9. Wysham C, et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin (AWARD-1). Diabetes Care. 2014;37:2159-2167.
10. U.S. Food and Drug Administration. FDA Adverse Event Reporting System (FAERS) public dashboard. FDA. 2024.
11. National Institute of Diabetes and Digestive and Kidney Diseases. Insulin, medicines, and other diabetes treatments. NIDDK. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Trulicity, Mounjaro, and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.